Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Advancing Two Innovative Platform Technologies

IMMUNE FX™ (IFx™): Personalized Cancer Vaccines Harnessing the Power of the Innate Immune Response

Our IFx technology is designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria and harness the power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.

Bi-Functional Antibody Drug Conjugates (ADCs)

Leveraging our proprietary Delta receptor technology we are developing first-in-class bi-functional antibody drug conjugates (ADCs) that target Myeloid Derived Suppressor Cells (MDSCs) to inhibit their immune suppressing effects of MDSCs on the tumor microenvironment. This may prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies, allowing them to continue working.

Pipeline

Sign Up For Alerts!